Synonyms: 1-[[5-Methyl-4-[[(phenylamino)carbonyl]amino]-2-furanyl]sulfonyl]piperidine; GSK 264220A; N-[2-Methyl-5-(1-piperidinylsulfonyl)-3-furanyl]-N'-phenylurea
Molecular Formula: C17H21N3O4S
Molecular Weight: 363.43
Linear Structural Formula: C17H21N3O4S
MDL Number: MFCD02679009
Purity: >=98% (HPLC)
Storage: 2-8C
Biochem Physiol Actions: GSK264220A is a potent, active site-targeting, covalent inhibitor against endothelial lipase (EL or LIPG; IC50 = 130 nM) and lipoprotein lipase (LPL or LIPD; IC50 = 100 nM). GSK264220A reduces NeuT expression - or CoCl2 treatment-induced intracellular triacylglycerol & lipid droplets (TAG & LD) increase in MCF-7 (16 & 32 nM) and suppresses LPL-depenent melanoma survival (by ~50% at 18.75 muM; WM852, WM1361). When applied in mice in vivo (30 mg/kg ip.), GSK264220A21 enhances lipid nanoparticles-mediated siRNAs delivery & gene-silencing efficacy.